Once the Pro-Infliximab encounters the overexpressed MMP-2/9 and is specifically hydrolyzed in the disease region of rheumatoid arthritis (RA), the cleaved Pro-Infliximab is specifically activated and neutralizes the target antigen to suppress RA progression (Fig. 2). The gene discussed is MMP2; the disease is rheumatoid arthritis.